Marie Pigeyre1,2,3, Jennifer Sjaarda1,2,4, Michael Chong1,2,4, Sibylle Hess5, Jackie Bosch1,6, Salim Yusuf1,7, Hertzel Gerstein1,3, Guillaume Paré8,2,4,7. 1. Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada. 2. Thrombosis and Atherosclerosis Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada. 3. Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. 4. Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. 5. R&D, Translational Medicine & Early Development, Biomarkers & Clinical Bioanalyses, Sanofi Aventis Deutschland GmbH, Frankfurt, Germany. 6. School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada. 7. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada. 8. Population Health Research Institute, David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton, Ontario, Canada pareg@mcmaster.ca.
Abstract
OBJECTIVE: To determine whether ACE inhibitors reduce the risk of type 2 diabetes using a Mendelian randomization (MR) approach. RESEARCH DESIGN AND METHODS: A two-sample MR analysis included 17 independent genetic variants associated with ACE serum concentration in 4,147 participants from the Outcome Reduction with Initial Glargine INtervention (ORIGIN) (clinical trial reg. no. NCT00069784) trial, and their effects on type 2 diabetes risk were estimated from 18 studies of the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium. A genetic risk score (GRS) underpinning lower ACE concentration was then tested for association with type 2 diabetes prevalence in 341,872 participants, including 16,320 with type 2 diabetes, from the UK Biobank. MR estimates were compared after standardization for blood pressure change, with the estimate obtained from a randomized controlled trial (RCT) meta-analysis of ACE inhibitors versus placebo (n = 31,200). RESULTS: Genetically lower ACE concentrations were associated with a lower risk of type 2 diabetes (odds ratio [OR] per SD 0.92 [95% CI 0.89-0.95]; P = 1.79 × 10-7). This result was replicated in the UK Biobank (OR per SD 0.97 [0.96-0.99]; P = 8.73 × 10-4). After standardization, the ACE GRS was associated with a larger decrease in type 2 diabetes risk per 2.4-mmHg lower mean arterial pressure (MAP) compared with that obtained from an RCT meta-analysis (OR per 2.4-mmHg lower MAP 0.19 [0.07-0.51] vs. 0.76 [0.60-0.97], respectively; P = 0.007 for difference). CONCLUSIONS: These results support the causal protective effect of ACE inhibitors on type 2 diabetes risk and may guide therapeutic decision making in clinical practice.
OBJECTIVE: To determine whether ACE inhibitors reduce the risk of type 2 diabetes using a Mendelian randomization (MR) approach. RESEARCH DESIGN AND METHODS: A two-sample MR analysis included 17 independent genetic variants associated with ACE serum concentration in 4,147 participants from the Outcome Reduction with Initial Glargine INtervention (ORIGIN) (clinical trial reg. no. NCT00069784) trial, and their effects on type 2 diabetes risk were estimated from 18 studies of the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium. A genetic risk score (GRS) underpinning lower ACE concentration was then tested for association with type 2 diabetes prevalence in 341,872 participants, including 16,320 with type 2 diabetes, from the UK Biobank. MR estimates were compared after standardization for blood pressure change, with the estimate obtained from a randomized controlled trial (RCT) meta-analysis of ACE inhibitors versus placebo (n = 31,200). RESULTS: Genetically lower ACE concentrations were associated with a lower risk of type 2 diabetes (odds ratio [OR] per SD 0.92 [95% CI 0.89-0.95]; P = 1.79 × 10-7). This result was replicated in the UK Biobank (OR per SD 0.97 [0.96-0.99]; P = 8.73 × 10-4). After standardization, the ACE GRS was associated with a larger decrease in type 2 diabetes risk per 2.4-mmHg lower mean arterial pressure (MAP) compared with that obtained from an RCT meta-analysis (OR per 2.4-mmHg lower MAP 0.19 [0.07-0.51] vs. 0.76 [0.60-0.97], respectively; P = 0.007 for difference). CONCLUSIONS: These results support the causal protective effect of ACE inhibitors on type 2 diabetes risk and may guide therapeutic decision making in clinical practice.
Authors: Jie V Zhao; Fangchao Liu; C Mary Schooling; Jianxin Li; Dongfeng Gu; Xiangfeng Lu Journal: Diabetologia Date: 2022-01-26 Impact factor: 10.122
Authors: América Liliana Miranda-Lora; Jenny Vilchis-Gil; Daniel B Juárez-Comboni; Miguel Cruz; Miguel Klünder-Klünder Journal: Front Endocrinol (Lausanne) Date: 2021-03-12 Impact factor: 5.555
Authors: James Yarmolinsky; Virginia Díez-Obrero; Tom G Richardson; Marie Pigeyre; Jennifer Sjaarda; Guillaume Paré; Venexia M Walker; Emma E Vincent; Vanessa Y Tan; Mireia Obón-Santacana; Demetrius Albanes; Jochen Hampe; Andrea Gsur; Heather Hampel; Rish K Pai; Mark Jenkins; Steven Gallinger; Graham Casey; Wei Zheng; Christopher I Amos; George Davey Smith; Richard M Martin; Victor Moreno Journal: PLoS Med Date: 2022-02-03 Impact factor: 11.069
Authors: Imadeldin Elfaki; Rashid Mir; Faisel M Abu Duhier; Maeidh A Alotaibi; Adel Ibrahim Alalawy; Jameel Barnawi; Abdullatif Taha Babakr; Mohammad Muzaffar Mir; Faris Altayeb; Hyder Mirghani; Ehab A M Frah Journal: Curr Issues Mol Biol Date: 2021-11-02 Impact factor: 2.976
Authors: Zhijian Yang; Erin Macdonald-Dunlop; James F Wilson; Xia Shen; Jiantao Chen; Ranran Zhai; Ting Li; Anne Richmond; Lucija Klarić; Nicola Pirastu; Zheng Ning; Chenqing Zheng; Yipeng Wang; Tingting Huang; Yazhou He; Huiming Guo; Kejun Ying; Stefan Gustafsson; Bram Prins; Anna Ramisch; Emmanouil T Dermitzakis; Grace Png; Niclas Eriksson; Jeffrey Haessler; Xiaowei Hu; Daniela Zanetti; Thibaud Boutin; Shih-Jen Hwang; Eleanor Wheeler; Maik Pietzner; Laura M Raffield; Anette Kalnapenkis; James E Peters; Ana Viñuela; Arthur Gilly; Sölve Elmståhl; George Dedoussis; John R Petrie; Ozren Polašek; Lasse Folkersen; Yan Chen; Chen Yao; Urmo Võsa; Erola Pairo-Castineira; Sara Clohisey; Andrew D Bretherick; Konrad Rawlik; Tõnu Esko; Stefan Enroth; Åsa Johansson; Ulf Gyllensten; Claudia Langenberg; Daniel Levy; Caroline Hayward; Themistocles L Assimes; Charles Kooperberg; Ani W Manichaikul; Agneta Siegbahn; Lars Wallentin; Lars Lind; Eleftheria Zeggini; Jochen M Schwenk; Adam S Butterworth; Karl Michaëlsson; Yudi Pawitan; Peter K Joshi; J Kenneth Baillie; Anders Mälarstig; Alexander P Reiner Journal: Circulation Date: 2022-04-07 Impact factor: 39.918
Authors: Dipender Gill; Marios Arvanitis; Paul Carter; Ana I Hernández Cordero; Brian Jo; Ville Karhunen; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy Mason; Evanthia Pashos; Ashis Saha; Vanessa Y Tan; Verena Zuber; Yohan Bossé; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem Hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Emanuele Di Angelantonio; Barbara E Engelhardt; James E Peters; Don D Sin; Stephen Burgess Journal: R Soc Open Sci Date: 2020-11-18 Impact factor: 3.653